June 21, 2023 Amendment to Form S-1 – Registration Statement Under The Securities Act Of 1933 – Ludwig Enterprises, Inc. – 47,000,000 Shares of Common Stock
This proposed S-1 offering prospectus relates to the offering of 47,000,000 shares of common stock of Ludwig Enterprises, Inc. The Offering document is requesting but has not yet received final SEC approval. Click Here To Download
Ludwig Enterprises Announces Stock Listing on the Canadian Stock Exchange
Sparks, NV – March 20, 2023: Ludwig Enterprises, Inc., OTC: LUDG,(Ludwig - The Genomics LanguageCompany ™) is pleased to announce itintends to file, in the second quarter of 2023,a Non-OfferingProspectus to enable the Companyto be listed on the Canadian Stock Exchange (CSE). “This corporate arrangement creates a great opportunity for Ludwig,” says Chief Science Officer Marvin S. Hausman MD. “Ludwig Enterprises and its subsidiary Precision Genomics have designed a genomicmRNA microarray assay that measures 48 different biomarkers of chronic inflammation
Ludwig Enterprises Developing New Partnerships to Fuel Growth
Sparks, NV – March 11, 2023: Ludwig Enterprises, Inc. (The Genomics Language Company™)is in discussions with several organizations that should contribute significantly to the company’s revenue growth. The Ludwig team has entered into discussions with a foreign developer of nutraceutical products to sell their products in the United States. They are also in discussions with an organization to conduct a diabetes clinical study utilizing mRNA Inflammatory Index™ to measure biomarkers for inflammation related to diabetes and its complications such as
Ludwig Enterprises mRNA Program Generating Broad Clinical Interest
Sparks, NV – March 11, 2023: Ludwig Enterprises, Inc. (The Genomics Language Company™) and its subsidiary Precision Genomics has attracted significant clinical interest in its patent pending mRNA Inflammatory Index™ which measures inflammatorybiomarkers that are associated with chronic diseases such as cancer, diabetes and heart disease. To date Precision Genomics has collected and is testing over 1700 samples from 28 different medical clinics along with detailed patient medical history. The company is receiving over 100 samples each month. The World
Ludwig Enterprises Develops Program to Support Ketamine Clinics
Sparks Nevada, March 6, 2023: Ludwig Enterprises, Inc, (OTC: LUDG), The Genomics Language Company™ is pleased to announce an agreement with Drs. Kim Farahay and Jeff Lee to provide them with the Company’s newly developed program for use of the mRNA Inflammatory Index™ in Ketamine treatment of patients with TreatmentResistant Depression.Drs. Farahay and Lee are finalizing plans to open a Ketamine clinic in southeastern Ohio in 2023. “Major depressive disorder is one of the leading causes of morbidity and all-cause
Ludwig Enterprises Launches Growth Plan
Sparks NV, February 13, 2023: Ludwig Enterprises (OTC: LUDG), developers of mRNA Inflammatory Index™(Patent Pending) and producers of NuGenea the anti-inflammatory nutraceutical is pleased to announcethat it has entered into an agreement with The Fannon Group, to provide healthcare sales and marketing leadership as they launchtheir flagship products towards the end of Q1 2023. “The Fannon Group and its CEO Luke is a great addition to the team,” said Anne Blackstone President of Ludwig Enterprises. “Luke and his team’sexpertise in
Ludwig Enterprises, Inc. Chief Medical Officer Lectures UCF Students on mRNAand Chronic Inflammation
February 9, 2023 – Orlando, Florida: Marvin Hausman MD, Chief Medical Officer ofLudwig Enterprises, Inc. and creator of the mRNA Inflammatory Index, lectured University of Central Florida graduate and pre-med students on the role of chronic inflammation in the development of diseases and how mRNA biomarkers may be the key to early detection of inflammation and the prevention of chronic illness. Chronic illnesses account for 70% of the deaths in the United States. There is growing evidence of a link
New Scientific Evidence Suggests How Chronic Illnesses May Be Prevented
Sparks Nevada/February 9, 2023: “Chronic inflammation is a silent disorder.” Writes Dr. Marvin S. Hausman MD in his white paper Inflammation: A Unifying Causation of Disease - Nutritional Intervention. “All people are being bombarded daily with chronic inflammation which is slowly waging a warof attrition on our tissues and organs. Picture air and water pollution, ionizing radiation from the sun, smoking, automobile emissions, etc. Most doctors only focus on observable inflammatory disease and symptoms in specific organs while the rest
Ludwig Enterprises, Inc. (OTC: LUDG) Prepares to Trade on the OTCQB Market
This is One More Step in Ludwig's Planned Path to an NYSE or NASDAQ Listing. SPARKS, NV / ACCESSWIRE / January 12, 2023 / (OTC PINK:LUDG) Ludwig Enterprises Inc., "The Genomics Language Company" ™ the parent company of Precision Genomics Inc., and mRNA for Life Inc., is pleased to announce that they have begun the application process to be approved to trade on the OTCQB Market. This is a significant step towards achieving the company's goal of up-listing to the NYSE. The
Ludwig Enterprises Receives IRB Approval on Bladder Cancer Study
Ludwig Enterprises Receives IRB Approval on Bladder Cancer StudymRNA Technology to Assess Patient Response to BCG Immunotherapy Treatment SPARKS, NV / ACCESSWIRE / January 3, 2023 / (OTC PINK:LUDG) Ludwig Enterprises,Inc., with its wholly owned subsidiary, Precision Genomics, Inc., creators of the mRNA Inflammatory Index™ (patent pending) which measures 48 different biomarkers of chronic inflammation, is pleased to announce Institutional Review Board (IRB) approval of a study titled "Using Measurements of mRNA and Elisa-based Cytokine/Protein Indices to Evaluate Pre- and Post-
Ludwig Enterprises and Subsidiary Precision Genomics Revealed Major Medical News During Sequire Spotlight Interview
Dr. Hausman Addressed How Precision Genomics mRNA technology can be a real breakthrough for significant chronic diseases. SPARKS, NV / ACCESSWIRE / November 16, 2022 / Precision Genomics, a Ludwig Enterprise Company (OTC:LUDG), is pleased to announce a SEQUIRE Spotlight featuring Dr. Marvin S. Hausman M.D. SEQUIRE Spotlight- Host Jonathan Miller interviews Chief Science Officer: Dr. Marvin S. Hausman. The featured interview includes in-depth information about the company's recent patent filing, upcoming bladder cancer study and the companies moves towards filing